Table of contents

Original Article

• A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer (1 May, 2008)

  J. D. Wright, A. A. Secord, T. M. Numnum, R. P. Rocconi, M. A. Powell, A. Berchuck, R. D. Alvarez, R. K. Gibb, K. Trinkaus, J. S. Rader, D. G. Mutch
• The influence of reproductive and hormonal factors on ovarian cancer survival (1 May, 2008)

  C. M. Nagle, C. J. Bain, A. C. Green, P. M. Webb
• A randomized study of screening for ovarian cancer: a multicenter study in Japan (1 May, 2008)

  H. Kobayashi, Y. Yamada, T. Sado, M. Sakata, S. Yoshida, R. Kawaguchi, S. Kanayama, H. Shigetomi, S. Haruta, Y. Tsuji, S. Ueda, T. Kitanaka
• Comorbidity and ovarian cancer survival in Denmark, 1995–2005: a population-based cohort study (1 May, 2008)

  M. S. Tetsche, M. Nørgaard, J. Jacobsen, P. Wogelius, H. T. Sørensen
• Prospective evaluation of weekly topotecan in recurrent platinum-resistant epithelial ovarian cancer (1 May, 2008)

  T. Le, L. Hopkins, K. A. Baines, L. Rambout, M. Fung-Kee-Fung
• An individual prediction of the future (disease-free) survival of patients with a history of early-stage cervical cancer, multistate model (1 May, 2008)

  Q. D. Pieterse, G. G. Kenter, P. H.C. Eilers, J. B.M.Z. Trimbos
• The use and understanding of CA125 as a tumor marker for ovarian cancer: a questionnaire-based survey (1 May, 2008)

  E. L. Moss, J. Hollingworth, M. Holland, D. J. Murphy, I. Fernando, T. M. Reynolds
• Combination of bleomycin, etoposide, and cisplatin for the treatment of advanced ovarian granulosa cell tumors (1 May, 2008)

  P. Pautier, M. Gutierrez-Bonnaire, A. Rey, I. Sillet-Bach, C. Chevreau, P. Kerbrat, P. Morice, P. Duvillard, C. Lhommé
• Population-based cohort follow-up study of all patients operated for borderline ovarian tumor in western Sweden during an 11-year period (1 May, 2008)

  M. Åkeson, B.-M. Zetterqvist, K. Dahllöf, A.-M. Jakobsen, M. BrännströM, G. Horvath
• Phase II multicenter open-label study of karenitecin in previously treated epithelial ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study (1 May, 2008)

  J. J. KAVANAGH, M. W. SILL, P. T. RAMIREZ, D. WARSHAL, M. L. PEARL, M. A. MORGAN
• Pathology of stage I versus stage III ovarian carcinoma with implications for pathogenesis and screening (1 May, 2008)

  A. V. YEMELYANOVA, J. A. COSIN, M. A. BIDUS, C. R. BOICE, J. D. SEIDMAN
• Glycomics analysis of serum: a potential new biomarker for ovarian cancer? (1 May, 2008)

  G. S. LEISEROWITZ, C. LEBRILLA, S. MIYAMOTO, H. J. AN, H. DUONG, C. KIRMIZ, B. LI, H. LIU, K. S. LAM
• Plasticity of ovarian cancer cell SKOV3ip and vasculogenic mimicry in vivo

  (1 May, 2008)

  M. SU, Y.-J. FENG, L.-Q. YAO, M.-J. CHENG, C.-J. XU, Y. HUANG, Y.-Q. ZHAO, H. JIANG
• Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance

  (1 May, 2008)

  R. SALANI, R. J. KURMAN, R. GIUNTOLI, G. GARDNER, R. BRISTOW, T.-L. WANG, I.-M. SHIH
• Significance of E2F-1 overexpression in epithelial ovarian cancer (1 May, 2008)

  D. S. SUH, M. S. YOON, K. U. CHOI, J. Y. KIM
• Expression of hypoxia-inducible factor 1α gene affects the outcome in patients with ovarian cancer (1 May, 2008)

  R. SHIMOGAI, J. KIGAWA, H. ITAMOCHI, T. IBA, Y. KANAMORI, T. OISHI, M. SHIMADA, S. SATO, W. KAWAGUCHI, N. TERAKAWA
• Expression of CD133-1 and CD133-2 in ovarian cancer (1 May, 2008)

  G. FERRANDINA, G. BONANNO, L. PIERELLI, A. PERILLO, A. PROCOLI, A. MARIOTTI, M. CORALLO, E. MARTINELLI, S. RUTELLA, A. PAGLIA, G. ZANNONI, S. MANCUSO, G. SCAMBIA
• Effects of anemia correction with epoetin beta in patients receiving radiochemotherapy for advanced cervical cancer (1 May, 2008)

  H.-G. STRAUSS, G. HAENSGEN, J. DUNST, C. R.W. HAYWARD, H.-U. BURGER, A. SCHERHAG, H. KOELBL
• Patterns of failure and prognostic factor analyses in locally advanced cervical cancer patients staged by magnetic resonance imaging and treated with curative intent (1 May, 2008)

  K. NARAYAN, R. J. FISHER, D. BERNSHAW
• Immunization of mice with plasmids coexpressing HPV16 E5 and the novel oncogene hWAPL

  (1 May, 2008)

  C. X CAO, J. MA, M. XUN, X. XUE, P. CHEN, Y. L CHU
• Extracellular regulated kinase-2 immunoreactivity increases in parallel with cervical intraepithelial neoplasia grade in cervical neoplasia (1 May, 2008)

  V. KAPETANIOS, A. C. LAZARIS, P. BOGRIS, S. KOUNELI, A. NONNI, H. ARVANITI, E. KOURI, M. TZAVARA, G. GIANNAKODIMOS, H. KOUTSELINI, E. S. PATSOURIS